References
- Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825–34. doi:https://doi.org/10.1056/NEJMoa1408913. PMID:25714160.
- Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, Simmons RL, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363–72. doi:https://doi.org/10.1097/00000658-200203000-00008. PMID:11882758.
- Louie TJ, Emery J, Krulicki W, Byrne B, Mah M, OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob. Agents Chemother. 2009;53:261–3. doi:https://doi.org/10.1128/AAC.01443-07.
- Buffie, C. G, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517:205–8 . doi:https://doi.org/10.1038/nature13828. PMID:25337874.
- Kelly, C. P, Kyne L. The host immune response to Clostridium difficile. J. Med. Microbiol. 2011;60:1070–9. doi:https://doi.org/10.1099/jmm.0.030015-0. PMID:21415200.
- Zar, F. A., Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 2007;45:302–7. doi:https://doi.org/10.1086/519265. PMID:17599306.
- Chang, J. Y, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 2008;197:435–8. doi:https://doi.org/10.1086/525047. PMID:18199029.
- Louie, T. J, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 2011;364:422–31. doi:https://doi.org/10.1056/NEJMoa0910812. PMID:21288078.
- Cornely, O. A, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 2012;12:281–9. doi:https://doi.org/10.1016/S1473-3099(11)70374-7. PMID:22321770.
- Mullane, K. M, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, Shue YK, Louie TJ, Gorbach SL. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin. Infect. Dis. 2011;53:440–7. doi:https://doi.org/10.1093/cid/cir404. PMID:21844027.
- Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, et al. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis. 2018;18:296–307.
- Chilton CH, Crowther G, Baines S, Todhunter SL, Freeman J, Locher HH, Athanasiou A, Wilcox MH. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother. 2014;69:697–705. doi:https://doi.org/10.1093/jac/dkt411. PMID:24128668.
- Locher HH, Pfaff P, Schroeder S, et al. Cadazolid, a novel quinolonyl-oxazolidinone antibiotic with potent activity against Clostridium difficile: in vitro antibacterial activity and propensity for resistance development, abstr C1-1346. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. 2012 Sep 7–11; San Francisco, CA. American Society for Microbiology, Washington, DC.
- Louie, T. J, Nord CE, Talbot GH, Wilcox M, Gerding DN, Buitrago M, Kracker H, Charef P, Cornely OA. A multicenter, double-blind, randomized, Phase 2 study evaluating the novel antibiotic, cadazolid, in patients with Clostridium difficile infection. Antimicrob. Agents Chemother. 2015;59:6266–73. doi:https://doi.org/10.1128/AAC.00504-15. PMID:26248357.
- Vickers RJ. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis. 2017 Jul;17(7):735–44. doi:https://doi.org/10.1016/S1473-3099(17)30235-9.
- Daley P, Louie T, Lutz JE, Khanna S, Stoutenburgh U, Jin M, Adedoyin A, Chesnel L, Guris D, Larson KB, et al. Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial. J Antimicrob Chemother. 2017;72:3462–3470.
- Van Nood, E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 2013;368:407–15. doi:https://doi.org/10.1056/NEJMoa1205037. PMID:23323867.
- Hota SS, Sales V, Tomlinson G, Salpeter MJ, McGeer A, Coburn B, Guttman DS, Low DE, Poutanen SM, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent clostridium difficile infection: an open label, randomized controlled trial. Clin Infect Dis. 2017 Feb 1;64(3):265–71. doi:https://doi.org/10.1093/cid/ciw731.
- Mamo Y, Woodworth MH, Wang T. Durability and Long-Term Clinical Outcomes of Fecal Microbiota Transplant (FMT) Treatment in Patients with Recurrent Clostridium difficile Infection. Clin Infect Dis. 2018;66:1705–1711. doi:https://doi.org/10.1093/cid/cix1097.
- Hamilton M, Weingarden A, Sadowsky M. Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 2012;107:761–7. doi:https://doi.org/10.1038/ajg.2011.482. PMID:22290405.
- Lee, C. H, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, Weese JS, Collins S, Moayyedi P, Crowther M, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315:142–9. doi:https://doi.org/10.1001/jama.2015.18098. PMID:26757463.
- Hamilton M, Weingarden A, Unno T, Khoruts A, Sadowsky MJ. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes. 2013;4:125–35. doi:https://doi.org/10.4161/gmic.23571. PMID:23333862.
- Gerding, D. N, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015;313:1719–27. doi:https://doi.org/10.1001/jama.2015.3725. PMID:25942722.
- Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, et al. Bezlotoxumab for prevention of recurrent clostridium difficile infection. N Engl J Med. 2017 Jan 26;376(4):305–17. doi:https://doi.org/10.1056/NEJMoa1602615.
- Ghose, C., Kelly, C. P. The prospect for vaccines to prevent Clostridium difficile infection. Infect. Dis. Clin. North Am. 2015;29:145–62. doi:https://doi.org/10.1016/j.idc.2014.11.013. PMID:25677708.
- Foglia G, Shah S, Luxemburger C, Pietrobon PJ, Clostridium difficile: development of a novel candidate vaccine. Vaccine. 2012;30:4307–09. doi:https://doi.org/10.1016/j.vaccine.2012.01.056. PMID:22682287.
- Tian, J. H, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine. 2012;30:4249–58. doi:https://doi.org/10.1016/j.vaccine.2012.04.045. PMID:22537987.
- Donald, R. G, Flint M, Kalyan N, Johnson E, Witko SE, Kotash C, Zhao P, Megati S, Yurgelonis I, Lee PK, et al. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology. 2013;159:1254–66. doi:https://doi.org/10.1099/mic.0.066712-0. PMID:23629868.